Fulcrum Therapeutics Statistics Share Statistics Fulcrum Therapeutics has 54.09M
shares outstanding. The number of shares has increased by -13.5%
in one year.
Shares Outstanding 54.09M Shares Change (YoY) -13.5% Shares Change (QoQ) 0% Owned by Institutions (%) 82.22% Shares Floating 47.95M Failed to Deliver (FTD) Shares 6,996 FTD / Avg. Volume 0.97%
Short Selling Information The latest short interest is 4.92M, so 9.11% of the outstanding
shares have been sold short.
Short Interest 4.92M Short % of Shares Out 9.11% Short % of Float 11.8% Short Ratio (days to cover) 8.11
Valuation Ratios The PE ratio is -29.96 and the forward
PE ratio is null.
Fulcrum Therapeutics's PEG ratio is
0.34.
PE Ratio -29.96 Forward PE n/a PS Ratio 3.64 Forward PS n/a PB Ratio 1.2 P/FCF Ratio -116.72 PEG Ratio 0.34
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Fulcrum Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 22.63,
with a Debt / Equity ratio of 0.04.
Current Ratio 22.63 Quick Ratio 22.63 Debt / Equity 0.04 Debt / EBITDA -0.47 Debt / FCF -3.46 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $1.78M Profits Per Employee $-216.11K Employee Count 45 Asset Turnover 0.31 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -29.52% in the
last 52 weeks. The beta is 2.47, so Fulcrum Therapeutics's
price volatility has been higher than the market average.
Beta 2.47 52-Week Price Change -29.52% 50-Day Moving Average 7.19 200-Day Moving Average 4.72 Relative Strength Index (RSI) 37.08 Average Volume (20 Days) 722,688
Income Statement In the last 12 months, Fulcrum Therapeutics had revenue of 80M
and earned -9.72M
in profits. Earnings per share was -0.17.
Revenue 80M Gross Profit 78.41M Operating Income -21.9M Net Income -9.72M EBITDA -18.24M EBIT -19.83M Earnings Per Share (EPS) -0.17
Full Income Statement Balance Sheet The company has 58.21M in cash and 8.63M in
debt, giving a net cash position of 49.58M.
Cash & Cash Equivalents 58.21M Total Debt 8.63M Net Cash 49.58M Retained Earnings -519.4M Total Assets 228.84M Working Capital 210.39M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -2.22M
and capital expenditures -278K, giving a free cash flow of -2.5M.
Operating Cash Flow -2.22M Capital Expenditures -278K Free Cash Flow -2.5M FCF Per Share -0.04
Full Cash Flow Statement Margins Gross margin is 98.01%, with operating and profit margins of -27.37% and -12.16%.
Gross Margin 98.01% Operating Margin -27.37% Pretax Margin -12.16% Profit Margin -12.16% EBITDA Margin -22.8% EBIT Margin -27.37% FCF Margin -3.12%
